AcelRx Pharmaceuticals, Inc. Forecast, price target & analysts
AcelRx Pharmaceuticals, Inc. Target price 2025 - Analyst rating & recommendation
AcelRx Pharmaceuticals, Inc. Classifications & Recommendation:
AcelRx Pharmaceuticals, Inc. Price Target
| Target Price | $3.57 |
| Price | $1.34 |
| Potential |
166.42%
register free of charge
|
| Number of Estimates | 5 |
|
5 Analysts have issued a price target AcelRx Pharmaceuticals, Inc. 2026 .
The average AcelRx Pharmaceuticals, Inc. target price is $3.57.
This is
166.42%
register free of charge
$6.30
370.15%
register free of charge
$3.03
126.12%
register free of charge
|
|
| A rating was issued by 9 analysts: 8 Analysts recommend AcelRx Pharmaceuticals, Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the AcelRx Pharmaceuticals, Inc. stock has an average upside potential 2026 of
166.42%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2031
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 0.00 | 0.03 |
| 100.00% |
5 Analysts have issued a sales forecast AcelRx Pharmaceuticals, Inc. 2025 . The average AcelRx Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
4 AcelRx Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2025. The average AcelRx Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2031
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.50 | -0.51 |
| 60.94% | 2.00% | |
| P/E | negative | |
| EV/Sales | 2,021.42 |
4 Analysts have issued a AcelRx Pharmaceuticals, Inc. forecast for earnings per share. The average AcelRx Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
AcelRx Pharmaceuticals, Inc....
Current AcelRx Pharmaceuticals, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 01 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 21 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 01 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 21 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
